Dr. Moshe Talpaz, MD
Medical Oncology (Medical Oncology Physician)
1500 East Medical Center Dr, B1 Floor Cancer Ctr Recp B
Ann Arbor, MI 48109
- Medicare participating
At a glance
- Years since graduation
- 51
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 57
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
MI license 4301086684 -
Internal Medicine Physician
MI license 4301086684
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Michigan Health System Ann Arbor, MI
Medical groups
- Regents of the University of Michigan (3,346 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 57
- Services billed
- 149
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 141 | 89 |
| Telephone medical discussion with physician, 21-30 minutes | 17 | 14 |
| Established patient office or other outpatient visit, 30-39 minutes | 15 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Jakafi (ruxolitinib phosphate) | 40 |
| Hydroxyurea Other prescribers in Ann Arbor, MI | 31 |
| Pegasys (peginterferon alfa-2a) | 17 |
| Scemblix (asciminib hydrochloride) | 13 |
| Deferasirox | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 10 payments worth $6,018 in total to this clinician.
| Incyte Corporation | $3,743 |
|---|---|
| Novartis Pharmaceuticals Corporation | $2,275 |
| Consulting Fee | $5,015 |
|---|---|
| Travel and Lodging | $878 |
| Food and Beverage | $125 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Incyte Corporation Aug 28, 2025 | Consulting Fee | $2,740 |
| Novartis Pharmaceuticals Corporation Jun 26, 2025 | Consulting Fee | $2,275 |
| Incyte Corporation Aug 22, 2025 | Travel and Lodging travel to Charlotte, NC | $402 |
| Incyte Corporation Aug 15, 2025 | Travel and Lodging travel to Charlotte, NC | $274 |
| Incyte Corporation Aug 24, 2025 | Travel and Lodging travel to Charlotte, NC | $70.97 |
| Incyte Corporation Aug 21, 2025 | Travel and Lodging travel to Charlotte, NC | $54.00 |
| Incyte Corporation Aug 15, 2025 | Travel and Lodging travel to Charlotte, NC | $52.95 |
| Incyte Corporation Aug 21, 2025 | Travel and Lodging travel to Charlotte, NC | $13.13 |
| Incyte Corporation Aug 22, 2025 | Travel and Lodging travel to Charlotte, NC | $11.12 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 4 companies. The companies reported $2,193,483 in research payments for these studies, mostly to the institutions running them.
- An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued Treatment
Novartis Pharmaceuticals Corporation - A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Hematological Malignancies) and Phase 2 (Dose Expansion of CPI0610 with and without Ruxo…
Novartis Pharmaceuticals Corporation - A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI 0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
Novartis Pharmaceuticals Corporation - A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Sumitomo Pharma America, Inc. · Recruiting · NCT04176198 - An Open-Label, Multicenter, Extension Study for Patients Previously Enrolled in Studies with Pelabresib
Novartis Pharmaceuticals Corporation - A Phase 1, Open label, Dose Escalation, Safety and Tolerability Study of INCB040093 in Subjects With Previously Treated B Cell Malignancies
Incyte Corporation - A phase 3 multi center open label randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase CML CP previously treated with 2 or more tyrosine kinase inhibitors
Novartis Pharmaceuticals Corporation - An open label, multi-center Phase IIIB study of Asciminib (ABL001) monotherapy in patients with chronic myelogenous leukemia on chronic phase (CML-CP) previously treated with at least 2 prior TKIs (tyrosine kinase inh…
Novartis Pharmaceuticals Corporation - A Phase 3b, Multicenter, Single-Arm, Open-Label Efficacy and Safety Study of Fedratinib in Subjects with DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High-Risk Primary Myelofibrosis (PMF), P…
Celgene Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.